HomeCoronary diseaseDrug-eluting stents

Drug-eluting stents

EuroPCR 2024 | 2 Year Outcomes of the New Sirolimus Eluting Bioadaptor vs Resolute Onyx Zotarolimus Elulting Stent

Stent related adverse events after the first year see a constant 2-3% annual increase, reaching 20% by...

Treatment of Recurrent In-Stent Restenosis with Drug-Eluting Stents: 10-Year Outcomes

In-stent restenosis (ISR) remains the main limitation in the percutaneous treatment of coronary artery disease, with a...

AGENT-IDE: Drug Coated Balloons for Instent Restenosis

Drug eluting stents (DES) have improved considerably over the years, reducing the initial indices of instent restenosis...

IN.PACT Outcomes at 5 Years

Over time, percutaneous coronary intervention (PCI) with drug coated balloons (DCB) have been shown more beneficial than...

LIFE-BTK | Critical Limb Ischemia: Use of Bioresorbable Scaffold in Infrapatellar Lesions (LIFE-BTK)

Advanced stages of peripheral artery disease cause significant limitations in patients, such as critical limb ischemia (CLI),...

Outcomes of the Use of Drug Coated Balloons in the Treatment of De Novo Coronary Lesions

Drug coated balloon (DCB) angioplasty offers a novel strategy for treating coronary artery disease. Studies assessing this...

iFR Guided PCI to the LAD: Same as for non-LAD Vessels?

iFR has been validated as a useful tool for intermediate lesion analysis, with the advantage of not...

ROTACUT Study: Rotational Atherectomy with Cutting Balloon for Stent Expansion Optimization

Approximately 30% of patients undergoing percutaneous coronary intervention (PCI) present moderate to severe calcified lesions, which presents...